The verdict
Our read at a glance.
Whether exact triptorelin evidence supports approved product-specific GnRH agonist contexts, and how to separate that evidence from non-U.S. labels, adjacent gynecology and breast-cancer study contexts, veterinary records, other GnRH-pathway drugs, compounded products, research-use products, internet-market products, and broad endocrine-optimization claims.
- The signal
- This memo draws on 72 vetted references. Current DailyMed and openFDA records anchor U.S. TRELSTAR and TRIPTODUR product contexts, while FDA GSRS, RxNorm, PubChem, NCI, TGA, EMA, ClinicalTrials.gov, and PubMed sources map identity, label status, registry status, prostate-cancer evidence, central precocious puberty evidence, adjacent endometriosis and breast/ovarian-suppression literature, comparator evidence, and safety signals.
- The unknown
- How future labels, safety communications, and comparative studies will change product-specific benefit-risk interpretation, and how cleanly public sources can keep triptorelin pamoate, triptorelin acetate, triptorelin embonate, TRELSTAR, TRIPTODUR, non-U.S. products, veterinary products, and comparator GnRH-pathway drugs separate.
- Our read
- Source-rich, but tightly bounded. Triptorelin has approved product-specific contexts and substantial human literature in defined endocrine-suppression settings; the Watchlist issue is preventing those sources from being generalized to broad wellness, generic hormone-pathway, or internet-market peptide claims.
The mechanism
How it works.
Triptorelin is a long-acting GnRH agonist, a synthetic ten-amino-acid analog of hypothalamic GnRH modified to last longer in the body. It binds pituitary GnRH receptors and initially provokes a burst of LH and FSH, but sustained, non-pulsatile exposure then desensitizes those receptors, so LH, FSH, and downstream sex-steroid production fall. That maintained suppression underlies its approved uses in advanced prostate cancer and central precocious puberty.
Safety & regulatory boundary
The consequential part.
The safety boundary is product- and population-specific. Label warnings, pediatric hypersensitivity literature, pharmacovigilance records, class cardiovascular reviews, hypoestrogenic or hypogonadal-state discussions, and comparator GnRH literature support a safety-watch frame, but pharmacovigilance signals cannot estimate incidence and class evidence cannot erase product distinctions.
What's next
What we're watching.
Watch DailyMed and openFDA label/status updates, FDA review or safety communications, ClinicalTrials.gov records, PubMed comparative safety studies, major-regulator records, and publications clarifying triptorelin salt, formulation, jurisdiction, and comparator boundaries.
Context
Why this is discussed.
Triptorelin sits in the same GnRH pathway as gonadorelin, leuprolide, and GnRH antagonist drugs. That makes it easy for public discussion to blur approved-product evidence with hormone, reproductive, wellness, bodybuilding, or peptide-market claims that the sources do not support.
The evidence base
72 cited references.
Regulatory & labels11
National Library of Medicine / FDA label · 2025-10-06
National Library of Medicine / FDA label · 2025-09-29
Food and Drug Administration / openFDA · API current 2026-05-15
Food and Drug Administration / openFDA · API current 2026-05-15
Food and Drug Administration · Checked 2026-05-19
Food and Drug Administration · Checked 2026-05-19
Food and Drug Administration / CDER · 2025 label
Food and Drug Administration / CDER · 2025-09-25
Therapeutic Goods Administration · ARTG date 2015-03-04
Therapeutic Goods Administration · 2015-09-17
European Medicines Agency · 2022-12-15
Registered trials6
ClinicalTrials.gov · NCT01467882
ClinicalTrials.gov · NCT01715129
ClinicalTrials.gov · NCT05029622
ClinicalTrials.gov · NCT03232281
ClinicalTrials.gov · NCT00066807
ClinicalTrials.gov · NCT01492972
Indexed literature (PubMed)50
Heyns CF et al. · 2003
Lundstrom EA et al. · 2009
Keating GM · 2010
Ploussard G et al. · 2013
Merseburger AS et al. · 2016
Fazeli F et al. · 2015
Kao CC et al. · 2012
Martinez-Pineiro L et al. · 2014
Klotz L et al. · 2024
Wu G et al. · 2024
Bolton EM et al. · 2018
Barrett R et al. · 2024
Chen Y et al. · 2025
Jia W et al. · 2025
Patel S et al. · 2025
Raja T et al. · 2022
Klein K et al. · 2016
Yu X et al. · 2024
Corripio R et al. · 2024
Valenzise M et al. · 2023
Zou S et al. · 2024
Dura-Trave T et al. · 2019
Bertelloni S et al. · 2018
The Medical Letter · 2018
Luo X et al. · 2023
Chiocca E et al. · 2012
Lasorella S et al. · 2020
Yoo E et al. · 2023
Park KH et al. · 2024
Durand A et al. · 2017
Martinez-Aguayo A et al. · 2006
Bertelloni S et al. · 2015
Pediatric center study · 2022
Leone Roberti Maggiore U et al. · 2014
Donnez J et al. · 2004
Bergqvist A et al. · 1998
Cirkel U et al. · 1995
Cheung TK et al. · 2000
Ferrero S et al. · 2011
Li X et al. · 2022
Zhu L et al. · 2022
Zhao AM et al. · 2026
Pagani O et al. · 2014
Lambertini M et al. · 2015
Lambertini M et al. · 2022
Bellet M et al. · 2016
Frampton JE · 2017
Ferraro E et al. · 2019
Kauffman RP et al. · 2021
Sponsor & other sources5
National Library of Medicine / RxNorm · Checked 2026-05-19
PubChem · Checked 2026-05-19
PubChem · Checked 2026-05-19
National Cancer Institute · Updated 2025-01-08
National Cancer Institute · Checked 2026-05-19
Keep reading